|
WO2007056362A2
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
EP2124974B1
(en)
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
|
EP2111414B1
(en)
|
2007-02-15 |
2014-07-02 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
ES2509883T3
(es)
|
2007-10-30 |
2014-10-20 |
Indiana University Research And Technology Corporation |
Antagonistas de glucagón
|
|
WO2009058734A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
EA019203B9
(ru)
|
2008-06-17 |
2014-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты глюкагонового рецептора/glp-1-рецептора
|
|
US9062124B2
(en)
|
2008-06-17 |
2015-06-23 |
Indiana University Research And Technology Corporation |
GIP-based mixed agonists for treatment of metabolic disorders and obesity
|
|
KR20110039230A
(ko)
|
2008-06-17 |
2011-04-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
|
|
TWI489992B
(zh)
|
2008-12-19 |
2015-07-01 |
印地安那大學研究及技術公司 |
醯胺系胰高血糖素超級家族之胜肽前驅藥物
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
|
AU2010272944B2
(en)
|
2009-07-13 |
2015-11-19 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
|
AR079345A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
|
JP5969461B2
(ja)
|
2010-04-27 |
2016-08-17 |
ジーランド ファーマ アクティーゼルスカブ |
Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用
|
|
EP2568993A4
(en)
|
2010-05-13 |
2014-02-19 |
Univ Indiana Res & Tech Corp |
GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
|
|
ES2661228T3
(es)
|
2010-05-13 |
2018-03-28 |
Indiana University Research And Technology Corporation |
Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
|
|
WO2011163012A2
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
PE20140186A1
(es)
|
2010-12-22 |
2014-02-13 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que presentan actividad de receptor de gip
|
|
WO2012150503A2
(en)
*
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
WO2012153196A2
(en)
*
|
2011-05-10 |
2012-11-15 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
SG195258A1
(en)
|
2011-06-10 |
2013-12-30 |
Hanmi Science Co Ltd |
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
|
PE20181268A1
(es)
|
2011-06-17 |
2018-08-03 |
Hanmi Science Co Ltd |
Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y el uso del mismo
|
|
GEP20176629B
(en)
|
2011-06-22 |
2017-02-27 |
Indiana Unversity Research And Tech Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
MX2013015168A
(es)
|
2011-06-22 |
2014-03-31 |
Univ Indiana Res & Tech Corp |
Co-agonista del receptor de glucagon/glp-1.
|
|
US9944687B2
(en)
|
2011-07-04 |
2018-04-17 |
Imperial Innovations Limited |
Compounds and their effects on feeding behaviour
|
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
|
KR20140097151A
(ko)
*
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
|
CA2875743A1
(en)
*
|
2012-06-14 |
2013-12-19 |
Sanofi |
Exendin-4 peptide analogues
|
|
JP6311708B2
(ja)
|
2012-06-21 |
2018-04-18 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｇｉｐ受容体活性を示すグルカゴンアナローグ
|
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
|
KR101968344B1
(ko)
*
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
KR101993393B1
(ko)
*
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
AR093387A1
(es)
|
2012-11-06 |
2015-06-03 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina
|
|
JP2016503046A
(ja)
*
|
2012-12-19 |
2016-02-01 |
ノヴォ ノルディスク アー／エス |
コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト
|
|
JP2016503771A
(ja)
|
2012-12-21 |
2016-02-08 |
サノフイ |
エキセンジン−４誘導体
|
|
CA2907454C
(en)
|
2013-03-21 |
2021-05-04 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of hydantoin containing peptide products
|
|
EP2976325B1
(en)
|
2013-03-21 |
2017-03-01 |
Sanofi-Aventis Deutschland GmbH |
Synthesis of cyclic imide containing peptide products
|
|
AR095986A1
(es)
|
2013-04-03 |
2015-11-25 |
Sanofi Sa |
Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
|
|
KR102302634B1
(ko)
|
2013-09-13 |
2021-09-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제 및 이의 조성물
|
|
AR098065A1
(es)
|
2013-10-17 |
2016-04-27 |
Zealand Pharma As |
Análogos de glucagón acilados
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
WO2015067715A2
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
EP3080155A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
JP6572497B2
(ja)
|
2013-12-18 |
2019-09-11 |
ザ・スクリップス・リサーチ・インスティテュート |
修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
|
|
RU2016134425A
(ru)
|
2014-02-18 |
2018-03-20 |
Ново Нордиск А/С |
Стабильные аналоги глюкагона и их применение для лечения гипогликемии
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
TWI802396B
(zh)
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
CN104926934B
(zh)
*
|
2014-09-23 |
2016-11-09 |
蒋先兴 |
胃泌酸调节素类似物
|
|
CR20170164A
(es)
|
2014-10-24 |
2017-08-29 |
Merck Sharp & Dohme |
Coagonistas de los receptores de glucagón y de glp-1
|
|
EP3985016A1
(en)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
US11135271B2
(en)
*
|
2014-12-30 |
2021-10-05 |
Hanmi Pharm. Co., Ltd. |
Glucagon derivatives with improved stability
|
|
KR20170137198A
(ko)
|
2015-04-16 |
2017-12-12 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
|
WO2016198628A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
|
|
US10696725B2
(en)
|
2015-06-30 |
2020-06-30 |
Hanmi Pharm. Co., Ltd. |
Glucagon derivative and a composition comprising a long acting conjugate of the same
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
WO2017062334A1
(en)
|
2015-10-05 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
|
EP3359194A4
(en)
|
2015-10-06 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
|
|
US10793615B2
(en)
|
2015-10-27 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
Long-acting co-agonists of the glucagon and GLP-1 receptors
|
|
US10493125B2
(en)
|
2015-12-09 |
2019-12-03 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and GLP-1 receptors
|
|
MX2018008027A
(es)
|
2015-12-31 |
2018-11-29 |
Hanmi Pharm Ind Co Ltd |
Activador triple que activa receptor de glucagon, glp-1 y gip.
|
|
US10869929B2
(en)
|
2016-01-29 |
2020-12-22 |
Merck Sharp & Dohme Corp. |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
|
CA3029518A1
(en)
*
|
2016-06-29 |
2018-01-04 |
Hanmi Pharm. Co., Ltd. |
Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
|
|
AR110299A1
(es)
|
2016-12-02 |
2019-03-13 |
Sanofi Sa |
Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
|
|
SG11201903938XA
(en)
|
2016-12-09 |
2019-05-30 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
|
CN108299553B
(zh)
*
|
2017-01-13 |
2021-07-16 |
博瑞生物医药（苏州）股份有限公司 |
胃泌酸调节素修饰物
|
|
CN106986924A
(zh)
*
|
2017-03-23 |
2017-07-28 |
中国药科大学 |
胃泌酸调节素（oxm）类似物及其应用
|
|
CN116854804A
(zh)
*
|
2017-08-16 |
2023-10-10 |
东亚St株式会社 |
酰化胃泌酸调节素肽类似物
|
|
BR112020005841A8
(pt)
|
2017-09-25 |
2023-04-11 |
Merck Sharp & Dohme |
Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas.
|
|
CN115109166A
(zh)
*
|
2017-11-24 |
2022-09-27 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
|
CN115304666A
(zh)
*
|
2017-11-24 |
2022-11-08 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的胰高血糖素类似物
|
|
CN111171135B
(zh)
*
|
2018-11-12 |
2023-04-07 |
天津药物研究院有限公司 |
具有双重受体激动作用的胰高血糖素衍生肽及其用途
|
|
WO2020125744A1
(zh)
|
2018-12-21 |
2020-06-25 |
江苏恒瑞医药股份有限公司 |
双特异性蛋白
|
|
US11471512B2
(en)
|
2019-03-01 |
2022-10-18 |
Merck Sharp & Dohme Llc |
Pharmaceutical compositions of a peptide
|
|
CN110684082B
(zh)
*
|
2019-10-08 |
2021-12-10 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
|
|
EP3842449A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled olefin co-agonists of the glucagon and glp-1 receptors
|
|
EP3842060A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled lactam co-agonists of the glucagon and glp-1 receptors
|
|
EP3842061A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled triazole co-agonists of the glucagon and glp-1 receptors
|
|
CN112898405B
(zh)
*
|
2021-01-22 |
2023-02-28 |
深圳市图微安创科技开发有限公司 |
多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
|
